Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress)
机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Cancer,Canc Hosp, Beijing, Peoples R China[2]Shandong First Med Univ & Shandong Acad Med Sci, Dept Med Oncol, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China[3]Peking Univ Canc Hosp & Inst, Dept Breast Oncol, Beijing, Peoples R China[4]Hebei Med Univ, Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China临床科室外一科河北医科大学第四医院[5]Peking Univ First Hosp, Dept Thyroid & Breast Surg, Beijing, Peoples R China[6]Xi An Jiao Tong Univ, Dept Med Oncol, Affiliated Hosp 1, Xian, Peoples R China[7]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China华中科技大学同济医学院附属协和医院[8]Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, Wuhan, Peoples R China
第一作者机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Cancer,Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Fan Y.,Li H.,Li H.,et al.Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress)[J].ANNALS OF ONCOLOGY.2024,35:S404-S405.doi:10.1016/j.annonc.2024.08.385.
APA：
Fan, Y.,Li, H.,Li, H.,Song, Z.,Xu, L....&Xu, B..(2024).Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress).ANNALS OF ONCOLOGY,35,
MLA：
Fan, Y.,et al."Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress)".ANNALS OF ONCOLOGY 35.(2024):S404-S405
医学